Fast And Furious: Lessons From China FDA's Innovation Push
This article was originally published in PharmAsia News
One year after the China FDA dashed out a flurry of policies to encourage innovative new drugs, a regulatory affairs veteran sheds light on how the policies are being implemented in practice and what lessons have been learned.
You may also be interested in...
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.